Sanders Melinda E, Schuyler Peggy A, Simpson Jean F, Page David L, Dupont William D
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Mod Pathol. 2015 May;28(5):662-9. doi: 10.1038/modpathol.2014.141. Epub 2014 Dec 12.
Opportunities to study the natural history of ductal carcinoma in situ are rare. A few studies of incompletely excised lesions in the premammographic era, retrospectively recognized as ductal carcinoma in situ, have demonstrated a proclivity for local recurrence in the original site. The authors report a follow-up study of 45 women with low-grade ductal carcinoma in situ treated by biopsy only, recognized retrospectively during a larger review of surgical pathology diagnoses and original histological slides for 26 539 consecutive breast biopsies performed at Vanderbilt, Baptist and St Thomas Hospitals in Nashville, TN from 1950 to 1989. Long-term follow-up was previously reported on 28 of these women. Sixteen women (36%) developed invasive breast carcinoma, all in the same breast and quadrant as their incident ductal carcinoma in situ. Eleven invasive breast carcinomas were diagnosed within 10 years of the ductal carcinoma in situ biopsy. Subsequent cases were diagnosed at 12, 23, 25, 29 and 42 years. Seven women, including one who developed invasive breast cancer 29 years after her ductal carcinoma in situ biopsy, developed distant metastasis, resulting in death 1-7 years postdiagnosis of invasive breast carcinoma. The natural history of low-grade ductal carcinoma in situ may extend more than four decades, with invasive breast cancer developing at the same site as the index lesion. This protracted natural history differs markedly from that of patients with high-grade ductal carcinoma in situ or any completely delimited ductal carcinoma in situ excised to negative margins. This study reaffirms the importance of complete margin evaluation in women treated with breast conservation for ductal carcinoma in situ as well as balancing recurrence risk with possible treatment-related morbidity for older women.
研究导管原位癌自然病史的机会很少。在乳腺钼靶检查前时代,对一些不完全切除的病变进行的少数研究,这些病变后来被回顾性地认定为导管原位癌,结果显示这些病变有在原部位局部复发的倾向。作者报告了一项对45例仅接受活检治疗的低级别导管原位癌女性患者的随访研究,这些病例是在对1950年至1989年在田纳西州纳什维尔的范德比尔特医院、浸信会医院和圣托马斯医院连续进行的26539例乳腺活检的手术病理诊断和原始组织学切片进行更大规模回顾时被回顾性认定的。之前已报道过其中28例女性患者的长期随访情况。16名女性(36%)发生了浸润性乳腺癌,均在其初发导管原位癌所在的同一乳房及象限。11例浸润性乳腺癌在导管原位癌活检后的10年内被诊断出来。后续病例分别在12年、23年、25年、29年和42年被诊断出来。7名女性发生了远处转移,其中1名在导管原位癌活检29年后发生浸润性乳腺癌,这些女性在浸润性乳腺癌诊断后1至7年死亡。低级别导管原位癌的自然病史可能会延续超过40年,浸润性乳腺癌在与索引病变相同的部位发生。这种漫长的自然病史与高级别导管原位癌患者或任何切缘阴性的完全切除的导管原位癌患者的情况明显不同。这项研究再次强调了对接受保乳治疗的导管原位癌女性进行切缘完整评估的重要性,以及在老年女性中平衡复发风险与可能的治疗相关 morbidity 的重要性。